Gene study aims to personalize blood thinner dosing
NCT ID NCT00162474
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how genetic differences in the CYP2C9 enzyme affect the way healthy volunteers process warfarin and similar drugs. Researchers will give participants single doses of one or more of these drugs and measure how their bodies break them down. The goal is to better understand why people respond differently to these medications, which could lead to safer, more personalized dosing in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Warfarin, Phenytoin, Losartan, Flurbiprofen, Siponimod
What this could lead to
If successful, this could help doctors predict the right dose of warfarin and similar drugs based on a person's genes, reducing side effects.
What could go wrong
This is an early-stage observational study in healthy people, not patients. The findings may not directly change clinical practice and need further validation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hadassah Medical Organization
RECRUITINGJerusalem, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact